Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Guselkumab Dose 2 Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 4 Interventional

A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751
View directory record Official record
Conditions
Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
Interventions
Breast Milk Sample Collection, Guselkumab
Procedure · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
52
States / cities
Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095
View directory record Official record
Conditions
Fistulizing Crohns Disease, Perianal Crohns Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03662542
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

NCT03649971
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT06563323
View directory record Official record
Conditions
Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Interventions
Guselkumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
63
States / cities
Arcadia, California • Coronado, California • Lancaster, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Guselkumab in Participants With Active Lupus Nephritis

NCT04376827
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Covina, California • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
32
States / cities
Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

NCT05784129
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
9
States / cities
San Diego, California • Naples, Florida • Macon, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

NCT01483599
View directory record Official record
Conditions
Psoriasis
Interventions
CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo
Drug
Lead sponsor
Janssen Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Guselkumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049
View directory record Official record
Conditions
Crohn Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
109
States / cities
Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT